title: Mifepristone label laws and trends in use: recent experiences in four US states.
authors.affiliation: Gynuity Health Projects, New York, NY, USA. Electronic address: wsheldon@gynuity.org.
authors.forename: Wendy R
authors.initials: WR
authors.lastname: Sheldon
authors.affiliation: Gynuity Health Projects, New York, NY, USA.
authors.forename: Beverly
authors.initials: B
authors.lastname: Winikoff
mesh_terms: D000021:Abortifacient Agents, Steroidal / Q000008:administration & dosage*; D000028:Abortion, Induced / Q000331:legislation & jurisprudence*; D002140:California; D003267:Contraception / Q000639:trends*; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D005260:Female; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage*; D009518:New York; D009820:Ohio; D011247:Pregnancy; D013781:Texas; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
chemical_list: D000021:Abortifacient Agents, Steroidal; D015735:Mifepristone